{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:28:09Z","timestamp":1781112489686,"version":"3.54.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s84782","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T23:52:23Z","timestamp":1462837943000},"page":"1627","source":"Crossref","is-referenced-by-count":16,"title":["Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date"],"prefix":"10.2147","author":[{"given":"Jos\u00e9 F.","family":"Vilela-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,5]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=30274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:45:18Z","timestamp":1477867518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/spotlight-on-valsartanacircsacubitril-fixed-dose-combination-for-heart-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s84782","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}